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Abstract 
Background: Regulatory T cells (Tregs) have been shown to limit anti-viral immunity during chronic retroviral infec-
tion and to restrict vaccine-induced T cell responses. The objective of the study was to assess whether a combina-
tional therapy of nanoparticle-based therapeutic vaccination and concomitant transient ablation of Tregs augments 
anti-viral immunity and improves virus control in chronically retrovirus-infected mice. Therefore, chronically Friend 
retrovirus (FV)-infected mice were immunized with calcium phosphate (CaP) nanoparticles functionalized with TLR9 
ligand CpG and CD8+ or CD4+ T cell epitope peptides (GagL85–93 or Env gp70123–141) of FV. In addition, Tregs were 
ablated during the immunization process. Reactivation of CD4+ and CD8+ effector T cells was analysed and the viral 
loads were determined.
Results: Therapeutic vaccination of chronically FV-infected mice with functionalized CaP nanoparticles transiently 
reactivated cytotoxic CD8+ T cells and significantly reduced the viral loads. Transient ablation of Tregs during nanopar-
ticle-based therapeutic vaccination strongly enhanced anti-viral immunity and further decreased viral burden.
Conclusion: Our data illustrate a crucial role for CD4+ Foxp3+ Tregs in the suppression of anti-viral T cell responses 
during therapeutic vaccination against chronic retroviral infection. Thus, the combination of transient Treg ablation 
and therapeutic nanoparticle-based vaccination confers robust and sustained anti-viral immunity.
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Background
Effector T cells are crucial for the elimination of intra-
cellular pathogens. Especially cytotoxic CD8+ T cells 
are predominantly important for the control of virus 
infections, i.e. human immunodeficiency virus (HIV) 
[1] or hepatitis C virus (HCV) [2, 3]. However, several 
evasion mechanisms of viruses, like viral evolution or 
exhaustion of effector T cells can contribute to persis-
tent infection. Important inducer of dysfunctional CD8+ 
T cells are virus-induced or virus-expanded regulatory 
T cells (Tregs). Tregs belong to a specialized T cell sub-
set which is characterized by the expression of the tran-
scription factor Foxp3 and unique suppressive capacities 
that can limit anti-viral immune responses [4–6]. It was 
demonstrated that the low responsiveness and reduced 
proliferation of virus-specific T cells during chronic 
viral infection is associated with the expansion of Tregs 
which also affects the cytotoxic activity of virus-specific 
CD8+ T cells [6, 7]. Immune-based therapies have been 
considered as potent approach to efficiently reactivate 
impaired anti-viral effector immunity to control chronic 
viral infection. In this concern, depletion of Tregs dur-
ing acute and chronic murine retroviral infection was 
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shown to restore the functions of CD8+ T cells and to 
decrease viral loads [5, 6, 8, 9]. The results suggest that 
Treg-mediated immunosuppression is a significant factor 
in the maintenance of chronic viral infections, and that 
Treg-targeted immunotherapy could be a valuable com-
ponent in therapeutic strategies to treat chronic retrovi-
ral infections.
Additionally, promising trials to efficiently reactivate 
CD8+ T cell responses have been made by confronting 
patient-derived dendritic cells (DCs) with HIV-specific 
antigens to induce virus-specific immune responses [10, 
11] or by directly targeting lymph nodes with peptide-
based vaccine vehicles [12]. In this context, nanoparticu-
late structures are discussed to be ideal vaccine delivery 
vehicles [13]. Inorganic calcium phosphate (CaP) nano-
particles are promising candidates for this purpose. Due 
to their small size (~100 nm) and their non-toxicity CaP 
nanoparticles feature ideal properties as delivery vehi-
cles across cell membranes [14, 15]. After functionali-
zation with TLR ligands such as CpG or poly(I:C), CaP 
nanoparticles efficiently activate cells of the innate and 
adaptive immune system [14]. In a recent study, we have 
shown that prophylactic immunization of mice with CaP 
nanoparticles, functionalized with virus-derived T cell 
epitopes and the TLR9 ligand CpG, leads to an activation 
of DCs and in consequence induced strong antigen-spe-
cific CD4+ and CD8+ T cell response. Of note, this vacci-
nation strategy resulted in a powerful protection against 
influenza virus and Friend retrovirus (FV) infection [16, 
17]. In addition, therapeutic vaccination of chronically 
FV-infected mice efficiently reactivated effector T cells 
which led to a significant decrease in viral loads.
FV is an immunosuppressive retrovirus complex of the 
non-pathogenic Friend murine leukemia virus (F-MuLV) 
and the pathogenic, replication defective spleen focus 
forming virus (SFFV) [18]. Disease-resistant mouse 
strains can control acute infection, but develop a life-long 
chronic infection. This is associated with the expansion 
and activation of Tregs [19], which down-regulate virus-
specific cytotoxic CD8+ T cell activity [6], a conspicu-
ous feature which in fact was also seen in HIV infection 
[20]. As no appropriate mouse model for studying HIV 
infection exists, the well-described FV infection model 
has been accepted to be suitable to understand basic con-
cepts in retroviral immunity and to test novel vaccination 
strategies [21–24].
In this study, we aimed to identify whether nanopar-
ticle-based vaccination and concomitant modulation 
of inhibitory Treg responses in chronically retrovirus 
infected mice results in potent anti-viral immunity and 
improves viral control. To our knowledge, we show for 
the first time that the combinational immune-based ther-
apy of CaP nanoparticle vaccination and Treg ablation 
efficiently reactivates the cytotoxic potential of CD8+ 
effector T cells and leads to a dramatic drop in viral loads 
in chronic retroviral infection, stronger than each thera-
peutic treatment regimen alone. Thus, vaccine-induced 
reactivation of effector T cells during chronic viral infec-
tion is feasible but is strikingly enhanced by simultaneous 
immune modulation.
Results
Therapeutic vaccination of chronically infected mice 
with functionalized CaP nanoparticles transiently 
reactivates cytotoxic CD8+ T cells and reduce viral loads
Recently, we introduced functionalized CaP nanopar-
ticles as excellent vaccination delivery system for the 
treatment of chronic retroviral infection [17]. Function-
alized triple-shell CaP nanoparticles were prepared by 
subsequent precipitation and functionalization steps as 
described earlier [14, 16]. In brief, CaP solid cores were 
loaded with CpG and CD8+ or CD4+ T cell epitope pep-
tides (GagL85–93 or Env gp70123–141) of FV and finally 
coated with a second layer of CaP and an outer shell of 
CpG for colloidal stabilization (Additional file  1: Fig-
ure  S1A). Vaccination of mice with functionalized CaP 
nanoparticles efficiently activates the major DC subsets, 
therefore mediating ideal requirements for the initiation 
of adaptive immune responses [14, 16]. One shot-immu-
nization of chronically FV infected mice with function-
alized CaP nanoparticles reactivated virus-specific T cell 
responses accompanied by a significant decrease in viral 
loads with striking advantage over vaccination with solu-
ble CpG ligand and viral peptides [17] (Additional file 1: 
Figure S1B–E).
Foxp3+ CD4+ regulatory T cells down‑regulate T cell 
responses after CaP nanoparticle vaccination
We recently demonstrated that therapeutic vaccination 
with CpG and FV-peptide functionalized CaP nanopar-
ticles decreases the proportion of immunosuppressive 
CD4+ regulatory T cells 7  days after therapeutic vacci-
nation [17]. Nonetheless, it was so far unclear if CD4+ 
regulatory T cells counteract an efficient effector T cells 
response after therapeutic vaccination. To analyze this 
issue, FV-resistant C57BL/6 mice were infected with 
a high dose of FV to induce chronic infection. 6  weeks 
after infection, mice were therapeutically vaccinated sub-
cutaneously with CpG/gp70/GagL functionalized CaP 
nanoparticles (Additional file 1: Figure S1B). Splenocytes 
were isolated from naïve, chronically infected (PBS), and 
therapeutically vaccinated mice (CaP nanoparticles) 7 
and 14 days after treatment, and the percentage of CD4+ 
regulatory T cells was determined. As expected, the pro-
portion of CD4+ regulatory T cells was decreased 7 days 
after vaccination with CaP nanoparticles compared to 
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PBS treated mice. However, we noticed that 14  days 
after vaccination this reduction was converted into an 
increase of CD4+ Foxp3+ regulatory T cells compared 
to PBS treated chronically infected mice (Fig.  1a). To 
understand this effect we particularly analyzed the ratio 
between effector and regulatory T cells at these respec-
tive time points. Interestingly, we found that the ratio of 
fully activated CD43+ CD4+ and CD43+ CD8+ effector 
T cells over CD4+ Foxp3+ regulatory T cells was signifi-
cantly elevated 7 days after CaP nanoparticle vaccination 
compared to PBS treatment; this effect was abolished 
14 days after vaccination (Fig. 1b). To check whether the 
increased regulatory T cell frequency on day 14 after vac-
cination was the result of cell proliferation we stained for 
the proliferation marker Ki67. Of note, no significant dif-
ferences were observed (Fig. 1c). As regulatory T cells are 
known to control virus-specific CD8+ T cell responses 
during chronic FV infection [5, 6, 25], we analyzed the 
correlation between CD8+ effector T cells and regulatory 
T cells during vaccination. Importantly, we were able to 
identify a strong negative correlation between the per-
centage of FV-specific CD8+ CD43+ GzmB+ T cells and 
percentage of CD4+ Foxp3+ T cells in the spleen 14 days 
after vaccination with CaP nanoparticles. The higher 
the percentage of CD4+ Foxp3+ regulatory T cells in 
the spleen the lower was the percentage of GzmB+ FV-
specific CD8+ T cells (Fig. 1d). Interestingly, this kind of 
correlation was not seen in the PBS treated control mice 
(Fig.  1d) nor at day 7 after vaccination which could be 
due to the change in the T effector-Treg ratios (data not 
shown). These results clearly demonstrate that although 
CD4+ and CD8+ effector T cells expand after therapeutic 
one shot-vaccination with functionalized CaP nanoparti-
cles, regulatory T cells still have a strong impact on virus-
specific immunity.
Transient ablation of regulatory T cells strongly enhances 
the therapeutic effect of functionalized CaP nanoparticles
Our results underline the powerful regulatory capacity 
of Foxp3+ T cells on CD8+ effector cells with cytotoxic 
potential during therapeutic vaccination of chronically 
FV-infected mice. To investigate whether ablation of 
regulatory T cells further improves the efficacy of func-
tionalized CaP nanoparticles for therapeutic vaccination, 
we investigated chronically FV infected DEREG (DEple-
tion of REGulatory T cells) mice in which regulatory T 
cells can be selectively ablated by the injection of diph-
theria toxin (DT) [26]. To ensure that the absence of 
Tregs will enhance cytotoxicity as well as T cell priming 
we decided to inject DEREG mice with DT 4 and 2 days 
before and 2 and 4 days after the vaccination with CpG/
gp70/GagL-functionalized CaP nanoparticles at week 
6 post FV infection (Fig. 2a), resulting in an up to 99 % 
depletion of Foxp3+ regulatory T cells in naïve, PBS, and 
CaP nanoparticle treated mice until day 7 post vaccina-
tion (Fig.  2b). On day 7 after vaccination, splenocytes 
were isolated and analyzed for the expression of GzmB 
by CD4+ and CD8+ effector T cells. Interestingly, the 
strongest increase in the frequency of activated cyto-
toxic CD4+ CD43+ GzmB+ and CD8+ CD43+ GzmB+ 
T cells was observed after the combination of CaP nano-
particle vaccination and depletion of regulatory T cells. 
Although the depletion of Tregs led also to an increase 
in gag-specific cytotoxic CD8+ T cells, the combination 
of CaP nanoparticle vaccination and Treg ablation even 
stronger increased the amount of those cells compared 
to DT treatment alone or CaP nanoparticle vaccination 
alone (Fig. 2c). In addition, ex vivo restimulation of sple-
nocytes with the GagL peptide revealed that the deple-
tion of regulatory T cells during vaccination further 
augmented the number of IFN-γ producing virus-specific 
CD8+ T cells compared to DT treatment or nanoparticle 
vaccination alone (Fig. 2d). The application of DT alone 
was not sufficient to significantly decrease the viral loads 
in mice. One shot-immunization with CpG/gp70/GagL-
functionalized CaP nanoparticles already reduced viral 
loads in the spleen, and this effect was further enhanced 
by depletion of regulatory T cells during the immuniza-
tion process (Fig. 3). These data clearly demonstrate that 
affecting the number of regulatory T cells before thera-
peutic vaccination could be crucial to effectively treat 
chronic viral infection. 
Antagonizing chemokine receptor 4 on regulatory T 
cells does not improve the anti‑viral effect of therapeutic 
vaccination with functionalized CaP nanoparticles
Depletion of regulatory T cells in humans, as performed 
in the transgenic DEREG mouse model, is  still elusive. 
Regulatory T cell depletion by anti-CD25 monoclonal 
antibodies can lead to enhanced immunity; however, a 
CD25-targeted approach is associated with several draw-
backs. First, regulatory T cell depletion might lead to 
appearance of autoimmune manifestations, as reported 
in experimental animals. Secondly, activated effector 
CD4+ and CD8+ T cells also express CD25 and could 
also be eliminated by CD25 depletion [27]. Therefore, 
alternative approaches, focusing on inhibition instead of 
depletion of regulatory T cells might be of high interest 
for upcoming therapies.
Blockade of chemokine receptor 4 (CCR4) by an 
antagonist was recently reported to inhibit migration 
of regulatory T cells to tumors, and thereby enhancing 
anti-tumor vaccination [28, 29]. Human and murine reg-
ulatory T cells, but not naïve or effector T cells express 
CCR4, and the ligands for CCR4, CCL22 and CCL17, are 
mainly secreted by activated DCs and macrophages. So 
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Fig. 1 Foxp3+ CD4+ regulatory T cells down-regulate T cell responses after CaP nanoparticle vaccination. a Frequencies of Foxp3+ CD4+ regulatory 
T cells were determined by flow cytometry in naïve and chronically FV-infected mice 7 and 14 days post vaccination (d.p.v.) with functionalized 
CaP nanoparticles. Representative dot plots of the analysis are shown. b Ratios of fully activated CD4+ CD43+ or CD8+ CD43+ effector T cells (EFF) 
to Foxp3+ CD4+ T cells. c Frequencies of Ki67+ Foxp3+ CD4+ regulatory T cells. d Correlation of the percentage of GzmB expressing tetramer 
stained FV-specific CD8+ T cells to frequencies of Foxp3+ CD4+ T cells 14 d.p.v. with PBS (left) or functionalized CaP NPs (right). Combined results of 
three independent experiments are shown. Bars represent mean ± SEM. Statistical analysis was performed by student’s t test. *p < 0.05; **p < 0.01; 
***p < 0.001
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Fig. 2 Transient ablation of regulatory T cells strongly enhances the therapeutic effect of functionalized CaP nanoparticles. a DEREG mice on 
C57BL/6 background were vaccinated as described in Additional file 1: Figure S1. In addition, mice were injected with 800 ng/mouse of diphtheria 
toxin (DT) 2 and 4 days before vaccination as well as 2 and 4 days after vaccination with functionalized CaP nanoparticles. b Frequencies of Foxp3+ 
CD4+ regulatory T cells and c GzmB expression by CD8+ or CD4+ CD43+ T cells in the spleen of naïve and FV chronically infected DEREG mice after 
vaccination 7 d.p.v. Representative dot plots are shown. d Splenocytes were isolated 7 d.p.v. from chronically FV infected DEREG mice treated with 
or without DT and restimulated ex vivo with 5 µg/ml of GagL85–93 or gp70123–141 peptide. After 24 h, the numbers of IFN-γ-producing CD4
+ and 
CD8+ T cells were determined by ELISpot. The figure illustrates the results of three independent experiments. 9 mice per group are shown. Bars 
represent mean ± SEM. One-way ANOVA followed by Bonferoni’s multiple comparison test was performed to analyze statistics of multiple group 
sets. *p < 0.05; **p < 0.01; ***p < 0.001
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far, it has not been tested if the combination of anti-viral 
vaccination with the blockade of CCR4 has a potentiating 
effect on the immune response. Therefore, we vaccinated 
chronically FV infected mice with functionalized CaP 
nanoparticles or with a combination of CaP nanoparti-
cles and an antagonist for CCR4, respectively. 7 days after 
vaccination T cell responses and viral loads were deter-
mined. Pretreatment of mice with a CCR4 antagonist 4 h 
before nanoparticle vaccination did not modulate the fre-
quencies of regulatory T cells in the spleen compared to 
nanoparticle vaccination alone nor did the combinational 
treatment enhance the CTL response (Fig. 4a). In conse-
quence, no differences in the viral loads were detectable 
between vaccination with nanoparticles and the combi-
national protocol (Fig. 4a). In addition, a prolonged inhi-
bition of regulatory T cell migration by treatment of mice 
4 h before and on day 1–4 after the vaccination did also 
not enhance anti-viral immunity (Fig. 4b). Consequently, 
treatment of mice with a CCR4 antagonist to inhibit the 
migration of regulatory T cells to the side of action does 
not represent an alternative approach for anti-retroviral 
therapy.
Discussion
Viruses such as HBV or HIV possess the ability to evade 
from the immune system by several mechanisms, like 
viral evolution or exhaustion of effector T cells which 
can lead to persistent infection. The currently available 
treatments for many of these chronic infections do not 
lead to satisfactory results. For example antiretroviral 
therapy (ART) is able to suppress HIV replication, the 
most prominent member of the retrovirus family, but the 
fact that HIV persists in reservoirs prevents HIV cure by 
ART. Therefore, there is a strong need to develop new 
strategies for therapeutic vaccination against chronic 
infection. Nanomaterials are discussed as part of poten-
tial immune-based therapeutic treatment to reactivate 
the host’s immune response [12, 30]. In our latest report, 
we demonstrated that the application of CpG and viral 
peptide functionalized CaP nanoparticles leads to signifi-
cant reactivation of T cell responses and improves virus 
control in murine chronic FV infection [17]. We also 
noticed that Tregs have a strong impact on virus-specific 
immune responses during chronic retrovirus infection 
[5]. They seem to have a significant effect on the cytotox-
icity of CD8+ T cells during acute chronic FV infection 
by inhibiting the production of cytotoxic molecules such 
as granzyme A and B [25]. Thus, the aim of the current 
study was to determine whether the combinational ther-
apy of nanoparticle-based vaccination with depletion of 
Tregs could strongly enhance the cytotoxic T cell (CTL) 
response and opens new options in the fight against 
chronic retroviral infection.
Our current study demonstrates that a combination of 
depletion of immunosuppressive Tregs and therapeutic 
immunization with functionalized CaP nanoparticles of 
chronically retrovirus infected mice significantly reduced 
viral loads by efficiently reactivating the cytotoxic poten-
tial of virus-specific CD8+ and CD4+ effector T cells 
compared to therapeutic vaccination alone. It therefore 
underlines the considerable influence of Tregs on the 
effector T cell response during immunotherapy which 
should be considered for the development of new vacci-
nation strategies.
Tregs are a subset of CD4+ T lymphocytes with the 
ability to down-regulate the immune system [31]. They 
are the key modulators of the establishment and/or 
maintenance of viral chronicity and constitute a barrier 
to efficient vaccination and immunotherapeutic strate-
gies [32]. The implication of regulatory T cells in chronic 
viral infection was first described in mice infected with 
FV [33, 34] and was then extended to other persistent 
viruses, including HIV [35], HBV [36], and HCV [2]. 
Especially for HIV patients, it was shown that Tregs simi-
larly to the situation in chronic FV infection accumulate 
in lymphoid tissues and suppress the anti-HIV response 
[35, 37]. Thus, it is becoming increasingly clear that con-
trolling this immunosuppressive cell subset would have 
widespread clinical applications to fight life-threatening 
viral diseases [38]. In addition, our current study shows 
evidence that the Treg population also counteracts the 
Fig. 3 Combinational therapy of regulatory T cell depletion 
and vaccination with functionalized CaP nanoparticles strongly 
enhances retroviral clearance. Chronically FV-infected DEREG mice 
were vaccinated as described in Fig. 2. 7 d.p.v., mice were sacrificed, 
and infectious centers in the spleen were determined. Results of 
four independent experiments were combined. Bars represent 
mean ± SEM. One-way ANOVA followed by Bonferoni’s multiple com-
parison test was performed to analyze statistics of multiple group 
sets. *p < 0.05
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Fig. 4 CCR4 antagonist treatment does not enhance vaccination efficacy. C57BL/6 mice were chronically infected with FV (>6 weeks) and thera-
peutically vaccinated either with PBS or functionalized CaP nanoparticles. In addition mice were injected with 2.5 µg CCR4 antagonist 4 h prior to 
vaccination (a) or in addition on day 1, 2, 3, and 4 post vaccination (b). 7 days later mice were sacrificed and analyzed for the percentages of Foxp3+ 
CD4+ T cells, CD43+ granzyme B expressing CD8+ T cells in the spleen are depicted. Infectious centers indicating the viral load in the spleen 7 days 
after vaccination in combination with 2.5 µg CCR4 antagonist 4 h prior or also on day 1, 2, 3 and 4 post vaccination (b) are shown. Results of one 
experiment are shown. Bars represent mean ± SEM. One-way ANOVA followed by Bonferoni’s multiple comparison test was performed to analyze 
statistics of multiple group sets
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effects of immunotherapeutic vaccination which implies 
that controlling this subset could further enhance immu-
notherapy. Suvas et al. [39] have shown that treatment of 
mice with anti-CD25 antibodies to impair the CD25high 
expressing Treg population resulted in enhanced antigen-
specific CD8+ T-cell responses accompanied by reduced 
viral burden in herpes simplex virus-1 infected mice. In 
addition, we could demonstrate in recent studies that 
ablation of Tregs from mCMV- and FV-infected mice by 
using DEREG (DEpletion of Treg) mice was associated 
with elevated anti-viral CD8+ T-cell responses showing 
a restored functionality [5, 40]. Also human studies have 
highlighted the effects of Tregs in suppressing antiviral 
effector responses. Macatangay et  al. [41] showed that 
reduced frequencies of virus-specific Tregs during vac-
cination are important for an efficient therapeutic anti-
HIV vaccine since this enables the broad activation of 
effector T cells. Furthermore, an decrease HIV-specific 
Treg response was associated with an effective DC-vac-
cine induced immunity in HIV-infected patients [42].
However, the depletion of Tregs should be done with 
caution since it is known that long term depletion of 
Tregs can lead to severe autoimmunity syndromes [43]. 
Temporary Treg depletion or the addition of a Treg 
blocker along with the vaccine should be considered. Par-
ticularly, transient inhibition of Treg migration by using 
small molecule antagonists to CCR4 was shown to pro-
vide robust antigen-specific CD8+ T cell responses dur-
ing anti-tumor vaccination [28, 29]. However, treatment 
of chronically FV-infected mice with a CCR4 antagonist 
before and/or during vaccination with functionalized 
CaP nanoparticles within our experimental setting did 
not improve the vaccination success. Therefore, further 
studies are needed to elucidate how to manipulate Treg 
numbers or function during anti-viral vaccination.
Several lines of evidence suggest now that the depletion 
of Tregs during therapeutic immunization of chronically 
retrovirus infected mice improves the vaccination efficacy 
of functionalized CaP nanoparticles. First, depletion of 
Tregs during immunization enhanced the relative number 
of virus-specific IFN-γ producing CD8+ T cells. Second, 
the strongest increase in the frequency of total activated 
virus-specific cytotoxic CD8+ CD43+ GzmB+ T cells was 
observed after a combined depletion of Tregs and immu-
nization. Since granzyme B has been associated with virus 
control and killing of virus infected cells in both FV and 
HIV infection [44, 45], induction of cytotoxic T cells is 
crucial for a therapeutic vaccine. Finally, depletion of 
Tregs during the therapeutic immunization of chronically 
FV-infected mice resulted in the lowest viral loads com-
pared to all other treatments tested in this study. Thus 
Tregs clearly control the CTL response induced by thera-
peutic vaccination and may reduce its effect.
Conclusion
Our findings underline that a combination of Treg abla-
tion and therapeutic nanoparticle-based vaccination con-




C57BL/6 mice were purchased from Harlan Laborato-
ries (Harlan Winkelmann GmbH, Borchen, Germany). 
DEREG (DEpletion of REGulatory T cells) mice (express-
ing eGFP and diphtheria toxin receptor under the control 
of the forkhead box P3 [Foxp3] promoter) on C57BL/6 
background were described previously [26]. All mice 
used in the experiments were 8–10  weeks old at time 
point of infection.
Cells and cell culture
A murine fibroblast cell line from Mus dunni was main-
tained in Roswell Park Memorial Institute (RPMI) 
medium containing 10 % FCS and 50 µg mL−1 penicillin/
streptomycin. Cell lines were maintained in a humidified 
5 % CO2 atmosphere at 37 °C.
Preparation of functionalized nanoparticles
CpG and viral peptide functionalized multi shell CaP 
nanoparticles were prepared as described previously 
[17]. Briefly, nanoparticles were prepared by fast mix-
ing of aqueous solutions of calcium nitrate (6.25  mM) 
and diammonium hydrogen phosphate (3.74  mM). 
Immediately after mixing, 1  mL of the calcium phos-
phate nanoparticle dispersion was mixed with 0.2  mL 
CpG (63  µM =  400  µg  mL−1) and 0.05  mL of the viral 
peptides GagL85–93 and gp70123–141 (1  mg  mL−1) were 
added to form an outer shell of biomolecules Then, cal-
cium nitrate solution (0.5 mL), diammonium phosphate 
solution (0.5 mL) and CpG solution (0.2 mL, 63 µM) were 
subsequently added to form further layers of calcium 
phosphate and CpG. This led to triple-shell nanoparti-
cles with the composition CaP/CpG + peptide/CaP/CpG 
(from core to shell). The final concentrations of CpG and 
GagL/gp70 peptide in the nanoparticle dispersion were 
65.3  µg  mL−1 (or 10.3  µM) and 20.4  µg  mL−1, respec-
tively. All inorganic salts were of p.a. (pro analysi) qual-
ity. The particles were characterized by scanning electron 
microscopy (SEM) and dynamic light scattering in the 
same way as described [17].
TLR‑ligand, viral peptides and CCR4 antagonist
The phosphorothioate-modified class B CpG 1826 was 
purchased from Eurofins MWG Operon (Ebersberg, 
Germany). The FV protein derived Gag and gp70 pep-
tide sequences containing MHC I and MHC II-restricted 
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epitopes were synthesized with the following sequences: 
GagL85–93, CCLCLTVFL; gp70123–141, EPLTSLTPRCN-
TAWNRLKL (JPT Peptide Technologies GmbH, Berlin 
Germany). The CCR4 antagonist CAS 864289-85-0 was 
purchased from Merck Millipore (Darmstadt, Germany).
Antibodies and flow cytometry
The monoclonal antibodies αCD4 (clone RM4-5), αCD8 
(clone 53–6.7) and αCD43 (clone 1B11) were obtained 
from BD Biosciences Pharmingen (Heidelberg, Ger-
many). Monoclonal anti-human allophycocyanin (APC)-
conjugated αGzmB antibody (clone GB12, Invitrogen, 
Karlsruhe, Germany) was used for intracellular granzyme 
B staining. The αFoxp3 antibody (clone FJK-16s) was pur-
chased from ebioscience (Frankfurt, Germany). Intracel-
lular staining with αFoxp3 and αGzmB was performed as 
described previously [17]. To detect FV-specific CD8+ T 
cells a PE-conjugated recombinant MHC-class I H2-Db 
tetramer (Beckman Coulter) presenting the FV GagL85-
93 peptide was used. Data was acquired by using an LSR 
II instrument using DIVA software (BD Biosciences).
Friend virus and chronic infection
A lactate dehydrogenase-elevating virus (LDV) containing 
B-cell-tropic, polycythemia-inducing Friend virus-com-
plex (FV) was obtained from BALB/c mouse spleen cell 
homogenate 14 days post infection. To induce chronic FV 
infection, naïve FV-resistant C57BL/6 mice were infected 
with 15,000 spleen focus forming units (SFFU).
Vaccination of mice
For anti-viral therapeutic vaccination of chronically FV 
infected and vaccination of naïve mice for in  vivo DC 
activation studies mice were immunized subcutaneously 
with 100  µL PBS or CaP nanoparticles functionalized 
with CpG/GagL/gp70 (10.3  µM CpG and 40.8  µg  mL−1 
GagL/gp70 peptide; CaP/CpG/GagL/gp70/CaP/CpG) in 
both hind footpads (50 µL each) 6 weeks post FV infec-
tion as described before [17].
Depletion of Foxp3+ regulatory T cells
To deplete Foxp3+ regulatory T cells, DEREG mice were 
injected intraperitoneally with diphtheria toxin (DT) 
(Merck, Germany) diluted in PBS. 800 ng in total per mouse 
was injected 4 and 2 days before as well as 2 and 4 days after 
vaccination with PBS or functionalized CaP NPs.
IFN‑γ ELISpot assay
Interferon-γ-producing cells were evaluated by ELIS-
pot with a mouse ELISPOTPLUS kit (MABTECH AB, 
Nacka Strand, Sweden). For evaluation of Interferon-γ-
producing cells after therapeutic vaccination of chroni-
cally infected mice, spleen cells or lymph node cells 
from a cell pool of brachial, axillary, inguinal, and pop-
liteal lymph nodes were restimulated. Restimulation of 
2.5  ×  105 cells was done with 5  µg  mL−1 GagL85–93 or 
gp70123–141 peptide in a 96-well ELISPOT plate for 24 h. 
IFN-γ-spots were stained according to the manufactur-
er’s instructions. After the plate was dried, the number 
of spots was counted by an AID ELISPOT reader using 
ELISPOT 6.0 software (Mabtech, Nacka Strand, Sweden).
Infectious center assay
Determination of viral loads by infectious center assay 
was performed as described previously [46]. Spleens were 
rinsed with RPMI containing 10 % FCS and 50 µg mL−1 
penicillin/streptomycin. Spleen cells were counted and 
serially diluted before seeding them onto Mus dunni cells 
and incubated under standard tissue culture conditions 
for 3  days, fixed with ethanol and labeled with the pri-
mary F-MuLV Env-specific MAb 720. After washing, a 
secondary horseradish peroxidase (HRP)-conjugated rab-
bit antimouse Ig antibody (Dako, Hambrug, Germany) 
was added. Foci representing infectious centers were 
detectable after adding of aminoethylcarbazole (Sigma-
Aldrich, Deisenhofen, Germany) as substrate for HRP. 
Foci were counted and infectious centers (IC)/spleen val-
ues were calculated.
Statistical analysis
Statistical analysis was performed by using student’s t test 
or One-way ANOVA to compare multiple groups using 
Bonferroni’s multiple comparison test. Data analysis was 
performed using Prism 6.0 software (GraphPad, La Jolla, 
CA). Statistical significance was set at the level of p < 0.05.
Ethics statement
Animal experiments were performed in strict accordance 
with institutional, state, and federal guidelines. The pro-
tocol was approved by the North Rhine-Westphalia State 
Agency for Nature, Environment and Consumer Protec-
tion (LANUF) (Permit Number: G1433/14). All efforts 
were made to minimize suffering.
Additional file
Additional file 1: Figure S1. A) Schematic illustration of functionalized 
multi shell calcium phosphate (CaP) nanoparticles. B) C57BL/6 mice were 
chronically infected with FV (>6 weeks) and therapeutically vaccinated 
either with PBS or functionalized CaP nanoparticles. 7 or 14 days post 
vaccination (d.p.v.), mice were sacrificed for analyzes. C) The percentage 
of CD4+ CD43+ and CD8+ CD43+ effector cells is shown. D) Frequency 
of granzyme B (GzmB) expressing CD43+ CD8+ T cells and CD43+ CD8+ 
FV-specific T cells identified by tetramer staining recognizing the H-2Db-
restricted FV gag epitope is depicted. E) 7 and 14 d.p.v., mice were sacri-
ficed, and infectious centers in the spleen were determined. The figure 
summarizes the results of 3 independent experiments. Statistical analysis 
was performed by student’s t-test. *p<0.05; **p<0.005.
Page 10 of 11Knuschke et al. Retrovirology  (2016) 13:24 
Authors’ contributions
TK designed the experiments, performed the experiments, analyzed the data, 
did the statistical analysis and wrote the paper. OR, WB, VS and WH carried out 
experiments. ME, JB and UD designed experiments. TS provide DEREG mice 
and designed experiments. AMW conceived the experiments and wrote the 
paper. All authors read and approved the final manuscript.
Author details
1 Institute of Medical Microbiology, University Hospital Essen, University 
of Duisburg-Essen, 45122 Essen, Germany. 2 Institute of Inorganic Chemis-
try and Center for Nanointegration (CeNIDE), University of Duisburg-Essen, 
45141 Essen, Germany. 3 Institute of Virology, University Hospital Essen, 
University of Duisburg-Essen, 45122 Essen, Germany. 4 Institute of Infection 
Immunology, TWINCORE, Centre for Experimental and Clinical Medicine, 
30625 Hannover, Germany. 
Acknowledgements
We thank Patrick Juszczak, Mechthild Hemmler-Roloff and Svenja Groten 
for excellent technical assistance. This work was supported by the Deutsche 
Forschungsgemeinschaft (SFB/Transregio 60 and GRK1949).
Competing interests
The authors declare that they have no competing interests.
Received: 16 February 2016   Accepted: 28 March 2016
References
 1. Hess C, Altfeld M, Thomas SY, et al. HIV-1 specific CD8+ T cells 
with an effector phenotype and control of viral replication. Lancet. 
2004;363(9412):863–6.
 2. Boettler T, Spangenberg HC, Neumann-Haefelin C, et al. T cells with a 
CD4+ CD25+ regulatory phenotype suppress in vitro proliferation of 
virus-specific CD8+ T cells during chronic hepatitis C virus infection. J 
Virol. 2005;79(12):7860–7.
 3. Seigel B, Bengsch B, Lohmann V, Bartenschlager R, Blum HE, Thimme R. 
Factors that determine the antiviral efficacy of HCV-specific CD8(+) T 
cells ex vivo. Gastroenterology. 2013;144(2):426–36.
 4. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat 
Immunol. 2005;6(4):353–60.
 5. Dietze KK, Zelinskyy G, Gibbert K, et al. Transient depletion of regula-
tory T cells in transgenic mice reactivates virus-specific CD8+ T cells 
and reduces chronic retroviral set points. Proc Natl Acad Sci USA. 
2011;108(6):2420–5.
 6. Zelinskyy G, Dietze K, Sparwasser T, Dittmer U. Regulatory T cells suppress 
antiviral immune responses and increase viral loads during acute infec-
tion with a lymphotropic retrovirus. PLoS Pathog. 2009;5(8):e1000406.
 7. Wherry EJ, Blattman JN, Ahmed R. Low CD8 T-cell proliferative potential 
and high viral load limit the effectiveness of therapeutic vaccination. J 
Virol. 2005;79(14):8960–8.
 8. Dietze KK, Zelinskyy G, Liu J, Kretzmer F, Schimmer S, Dittmer U. 
Combining regulatory T cell depletion and inhibitory receptor 
blockade improves reactivation of exhausted virus-specific CD8+ 
T cells and efficiently reduces chronic retroviral loads. PLoS Pathog. 
2013;9(12):e1003798.
 9. Zelinskyy G, Dietze KK, Husecken YP, et al. The regulatory T-cell response 
during acute retroviral infection is locally defined and controls the mag-
nitude and duration of the virus-specific cytotoxic T-cell response. Blood. 
2009;114(15):3199–207.
 10. Garcia F, Climent N, Guardo AC, et al. A dendritic cell-based vaccine elicits 
T cell responses associated with control of HIV-1 replication. Sci Transl 
Med. 2013;5(166):166ra2.
 11. Levy Y, Thiebaut R, Montes M, et al. Dendritic cell-based therapeutic 
vaccine elicits polyfunctional HIV-specific T-cell immunity associated with 
control of viral load. Eur J Immunol. 2014;44(9):2802–10.
 12. Liu H, Moynihan KD, Zheng Y, et al. Structure-based program-
ming of lymph-node targeting in molecular vaccines. Nature. 
2014;507(7493):519–22.
 13. Sahdev P, Ochyl LJ, Moon JJ. Biomaterials for nanoparticle vaccine deliv-
ery systems. Pharm Res. 2014;31(10):2563–82.
 14. Sokolova V, Knuschke T, Kovtun A, Buer J, Epple M, Westendorf AM. The 
use of calcium phosphate nanoparticles encapsulating Toll-like receptor 
ligands and the antigen hemagglutinin to induce dendritic cell matura-
tion and T cell activation. Biomaterials. 2010;31(21):5627–33.
 15. Sokolova V, Kozlova D, Knuschke T, Buer J, Westendorf AM, Epple M. 
Mechanism of the uptake of cationic and anionic calcium phosphate 
nanoparticles by cells. Acta Biomater. 2013;9(7):7527–35.
 16. Knuschke T, Sokolova V, Rotan O, et al. Immunization with biodegradable 
nanoparticles efficiently induces cellular immunity and protects against 
influenza virus infection. J Immunol. 2013;190(12):6221–9.
 17. Knuschke T, Bayer W, Rotan O, et al. Prophylactic and therapeutic vaccina-
tion with a nanoparticle-based peptide vaccine induces efficient protec-
tive immunity during acute and chronic retroviral infection. Nanomedi-
cine. 2014;10(8):1787–98.
 18. Hasenkrug KJ, Dittmer U. Immune control and prevention of chronic 
Friend retrovirus infection. Front Biosci. 2007;12:1544–51.
 19. Joedicke JJ, Myers L, Carmody AB, et al. Activated CD8 + T cells induce 
expansion of Vbeta5+ regulatory T cells via TNFR2 signaling. J Immunol. 
2014;193(6):2952–60.
 20. Chevalier MF, Weiss L. The split personality of regulatory T cells in HIV 
infection. Blood. 2013;121(1):29–37.
 21. Bayer W, Tenbusch M, Lietz R, et al. Vaccination with an adenoviral vec-
tor that encodes and displays a retroviral antigen induces improved 
neutralizing antibody and CD4+ T-cell responses and confers enhanced 
protection. J Virol. 2010;84(4):1967–76.
 22. Dittmer U, Brooks DM, Hasenkrug KJ. Requirement for multiple lympho-
cyte subsets in protection by a live attenuated vaccine against retroviral 
infection. Nat Med. 1999;5(2):189–93.
 23. Ohs I, Windmann S, Wildner O, Dittmer U, Bayer W. Interleukin-encoding 
adenoviral vectors as genetic adjuvant for vaccination against retroviral 
infection. PLoS One. 2013;8(12):e82528.
 24. Ruan KS, Lilly F. Approach to a retrovirus vaccine: immunization of mice 
against Friend virus disease with a replication-defective Friend murine 
leukemia virus. Proc Natl Acad Sci USA. 1992;89(24):12202–6.
 25. Zelinskyy G, Werner T, Dittmer U. Natural regulatory T cells inhibit produc-
tion of cytotoxic molecules in CD8(+) T cells during low-level Friend 
retrovirus infection. Retrovirology. 2013;10:109.
 26. Lahl K, Loddenkemper C, Drouin C, et al. Selective depletion of Foxp3+ 
regulatory T cells induces a scurfy-like disease. J Exp Med. 2007;204(1):57–63.
 27. de Vries IJ, Castelli C, Huygens C, et al. Frequency of circulating Tregs 
with demethylated FOXP3 intron 1 in melanoma patients receiving 
tumor vaccines and potentially Treg-depleting agents. Clin Cancer Res. 
2011;17(4):841–8.
 28. Bayry J, Tartour E, Tough DF. Targeting CCR4 as an emerging strategy for 
cancer therapy and vaccines. Trends Pharmacol Sci. 2014;35(4):163–5.
 29. Bayry J, Tchilian EZ, Davies MN, et al. In silico identified CCR4 antagonists 
target regulatory T cells and exert adjuvant activity in vaccination. Proc 
Natl Acad Sci USA. 2008;105(29):10221–6.
 30. Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and 
eradication. Science. 2014;345(6193):169–74.
 31. Wan YY. Regulatory T cells: immune suppression and beyond. Cell Mol 
Immunol. 2010;7(3):204–10.
 32. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat 
Rev Immunol. 2006;6(4):295–307.
 33. Iwashiro M, Peterson K, Messer RJ, Stromnes IM, Hasenkrug KJ. CD4(+) T 
cells and gamma interferon in the long-term control of persistent friend 
retrovirus infection. J Virol. 2001;75(1):52–60.
 34. Zelinskyy G, Kraft AR, Schimmer S, Arndt T, Dittmer U. Kinetics of CD8+ 
effector T cell responses and induced CD4+ regulatory T cell responses 
during Friend retrovirus infection. Eur J Immunol. 2006;36(10):2658–70.
 35. Nilsson J, Boasso A, Velilla PA, et al. HIV-1-driven regulatory T-cell accumu-
lation in lymphoid tissues is associated with disease progression in HIV/
AIDS. Blood. 2006;108(12):3808–17.
 36. Nan XP, Zhang Y, Yu HT, et al. Circulating CD4+ CD25 high regulatory T 
cells and expression of PD-1 and BTLA on CD4+ T cells in patients with 
chronic hepatitis B virus infection. Viral Immunol. 2010;23(1):63–70.
 37. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferen-
tially maintain highly functional HIV-specific CD8+ T cells. Blood. 
2006;107(12):4781–9.
Page 11 of 11Knuschke et al. Retrovirology  (2016) 13:24 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 38. Maizels RM, Smith KA. Regulatory T cells in infection. Adv Immunol. 
2011;112:73–136.
 39. Suvas S, Kumaraguru U, Pack CD, Lee S, Rouse BT. CD4+ CD25+ T cells 
regulate virus-specific primary and memory CD8+ T cell responses. J Exp 
Med. 2003;198(6):889–901.
 40. Jost NH, Abel S, Hutzler M, et al. Regulatory T cells and T-cell-derived IL-10 
interfere with effective anti-cytomegalovirus immune response. Immunol 
Cell Biol. 2014;92(10):860–71.
 41. Macatangay BJ, Szajnik ME, Whiteside TL, Riddler SA, Rinaldo CR. Regula-
tory T cell suppression of Gag-specific CD8 T cell polyfunctional response 
after therapeutic vaccination of HIV-1-infected patients on ART. PLoS 
One. 2010;5(3):e9852.
 42. Seddiki N, Brezar V, Draenert R. Cell exhaustion in HIV-1 infection: role of 
suppressor cells. Curr Opin HIV AIDS. 2014;9(5):452–8.
 43. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat 
Rev Immunol. 2008;8(7):523–32.
 44. Migueles SA, Osborne CM, Royce C, et al. Lytic granule loading of CD8+ T 
cells is required for HIV-infected cell elimination associated with immune 
control. Immunity. 2008;29(6):1009–21.
 45. Zelinskyy G, Balkow S, Schimmer S, Werner T, Simon MM, Dittmer U. The 
level of friend retrovirus replication determines the cytolytic pathway of 
CD8+ T-cell-mediated pathogen control. J Virol. 2007;81(21):11881–90.
 46. Dittmer U, Hunsmann G. Antiviral CD4 cell response in simian immuno-
deficiency virus-infected macaques. J Infect Dis. 1998;177(6):1771–2.
